Valneva SE | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
EUR0.06 |
Market Cap |
EUR295.92 M |
Shares Outstanding |
77.58 M |
Public Float |
- |
Valneva SE Pfd. | |
Stock Exchange | Euronext Paris |
EPS |
EUR0.02 |
Market Cap |
EUR7.95 M |
Shares Outstanding |
17.84 M |
Public Float |
17.83 M |
Valneva SE | |
Stock Exchange | Euronext Paris |
EPS |
EUR0.06 |
Market Cap |
EUR295.92 M |
Shares Outstanding |
90.92 M |
Public Float |
61.14 M |
Valneva SE | |
Stock Exchange | Wiener Boerse AG |
EPS |
EUR0.06 |
Market Cap |
EUR295.92 M |
Shares Outstanding |
77.58 M |
Public Float |
- |
Valneva SE Pfd. | |
Stock Exchange | Wiener Boerse AG |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
- |
Public Float |
- |
Address |
Campus Bio-Ouest 6 Saint-Herblain Lorraine 44800 France |
Employees | - |
Website | http://www.valneva.com |
Updated | 07/08/2019 |
Valneva SE is a biotech company which engages in the development, production, and marketing of vaccine and preventive medicine. It operates through the following segments: Commercialized Vaccines, Technologies and Services, and Vaccine Candidates. The Commercialized Vaccines segment includes currently marketed vaccines of the group such as JEV and DUKORAL. |